PATENT
Attorney Docket **044481-5043**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application: **Deborah Ann Law *et al.***

Application No. **09/673,302**

Group Art Unit: **1632**

Filed: **March 23, 2001**

Examiner: **Thaian N. Ton**

For: **Transgenic Mammals Expressing Mutant GP IIIa**

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL FORM

1. Transmitted herewith is a Sequence Listing in response to the Office Communication dated March 6, 2002 (Paper No. 12).

2. Extension of Time: The proceedings herein are for a patent application and the provisions of 37 C.F.R. § 1.136(a) apply. Applicants do not believe an extension of time is required with the filing of this paper. The due date for reply is April 6, 2002. Since April 6, 2002 is a Saturday, the reply is timely filed the next business day, Monday, April 8, 2002. However, this conditional petition is being made to provide for the possibility that Applicants have inadvertently overlooked the need for a petition and fee for an extension of time. The Commissioner is hereby authorized to charge any additional fees which may be required, including fees due under 37 C.F.R. § 1.16 and § 1.17, or credit any overpayment to Deposit Account 50-0310.

3. Additional Papers Filed:
   (i) Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
   (ii) Copy of Raw Sequence Listing Error Report
   (iii) Statement Accompanying Sequence Listing
   (iv) Sequence Listing – 9 pages
   (v) Computer Diskette with electronic copy of Sequence Listing
   (vi) Information Disclosure Statement Under 37 C.F.R. § 1.97(c)
   (vii) Form PTO-1449
   (viii) Copies of 6 documents and international search report

4. Fee Payment: The Commissioner is hereby authorized to charge **$180.00** to Deposit Account No. 50-0310 for payment of the Information Disclosure Statement fee.

5. Constructive Petition: **Except** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and § 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Respectfully submitted
Morgan, Lewis & Bockius LLP

Dated: **April 8, 2002**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
202-739-3000

Suzanne E. Ziska, Ph.D.
Registration No. 43,371

Application No.: 09/673,302

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990, see p. 32, lines 35-36.

☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☐ 7. Other:

Applicant Must Provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
PatentIn Software Program Support (SIRA)
Technical Assistance.....703-287-0200
To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

1632

#7
2-1-02
P.2

RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/673,302
Source: OIPE
Date Processed by STIC: 1/16/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) **INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,**
2) **TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY**

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.
PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)
PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO **REDUCE** ERRORED SEQUENCE LISTINGS, **PLEASE** USE THE **CHECKER VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:
http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.
Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom, including:

1. EFS-Bio (<**http://www.uspto.gov/ebc/efs/downloads/documents.htm**> , **EFS Submission User Manual** - ePAVE)
2. U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. **Hand Carry directly to:**
   U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
   Or
   U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. **Federal Express, United Parcel Service, or other delivery service to:** U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION SERIAL NUMBER: 09/673,302

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1	Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor **after** creating it. Please adjust your right margin to .3; this will prevent "wrapping."
2	Invalid Line Length	The rules require that a line **not exceed** 72 characters in length. This includes white spaces.
3	Misaligned Amino Numbering	The numbering under each 5th amino acid is misaligned. Do **not** use tab codes between numbers; use **space characters**, instead.
4	Non-ASCII	The submitted file was **not** saved in ASCII(DOS) text, as **required** by the Sequence Rules. **Please ensure your subsequent submission is saved in ASCII text.**
5	J Variable Length	Sequence(s) 2 contain n's or Xaa's representing more than one residue. **Per Sequence Rules, each n or Xaa can only represent a single residue.** Please present the **maximum** number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6	PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) _____. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. **This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.**
7	Skipped Sequences (OLD RULES)	Sequence(s) _____ missing. If intentional, please insert the following lines for **each** skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to **include** the skipped sequences.
8	Skipped Sequences (NEW RULES)	Sequence(s) _____ missing. If **intentional**, please insert the following lines for **each** skipped sequence. <210> sequence id number <400> sequence id number 000
9	Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of **n** or **Xaa**, and which residue **n** or **Xaa** represents.
10	Invalid <213> Response	Per 1.823 of Sequence Rules, the only **valid** <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is **required** when <213> response is Unknown or is Artificial Sequence
11	Use of <220>	Sequence(s) _____ missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
12	PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
13	Misuse of n	n can only be used to represent a single **nucleotide** in a nucleic acid sequence. N is **not** used to represent any value not specifically a nucleotide.

OIPE

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/673,302

DATE: 01/16/2002
TIME: 18:30:22

Input Set : A:\CO5043US.txt
Output Set: N:\CRF3\01162002\I673302.raw

pp 5,3-4

Does Not Comply
Corrected Diskette Needed

<110> APPLICANT: COR Therapeutics, Inc.
LAW, Deborah Ann
PHILLIPS, David R.

<120> TITLE OF INVENTION: Transgenic Mammals Expressing Mutant GPIIIa

<130> FILE REFERENCE: 44481-5043-US

<140> CURRENT APPLICATION NUMBER: US 09/673,302

<141> CURRENT FILING DATE: 2001-03-23

<150> PRIOR APPLICATION NUMBER: PCT/US99/08285

<151> PRIOR FILING DATE: 1999-04-15

<150> PRIOR APPLICATION NUMBER: US 60/115,516

<151> PRIOR FILING DATE: 1998-04-15

<160> NUMBER OF SEQ ID NOS: 8

<170> SOFTWARE: PatentIn version 3.1

<210> SEQ ID NO: 1

<211> LENGTH: 762

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<220> FEATURE:

<221> NAME/KEY: misc_feature

<223> OTHER INFORMATION: Glycoprotein IIIa

<400> SEQUENCE: 1

```
Gly Pro Asn Ile Cys Thr Thr Arg Gly Val Ser Ser Cys Gln Gln Cys
1               5                  10                  15
Leu Ala Val Ser Pro Met Cys Ala Trp Cys Ser Asp Glu Ala Leu Pro
            20                  25                  30
Leu Gly Ser Pro Arg Cys Asp Leu Lys Glu Asn Leu Leu Lys Asp Asn
        35                  40                  45
Cys Ala Pro Glu Ser Ile Glu Phe Pro Val Ser Glu Ala Arg Val Leu
    50                  55                  60
Glu Asp Arg Pro Leu Ser Asp Lys Gly Ser Gly Asp Ser Ser Gln Val
65                  70                  75                  80
Thr Gln Val Ser Pro Gln Arg Ile Ala Leu Arg Leu Arg Pro Asp Asp
                85                  90                  95
Ser Lys Asn Phe Ser Ile Gln Val Arg Gln Val Glu Asp Tyr Pro Val
            100                 105                 110
Asp Ile Tyr Tyr Leu Met Asp Leu Ser Tyr Ser Met Lys Asp Asp Leu
        115                 120                 125
Trp Ser Ile Gln Asn Leu Gly Thr Lys Leu Ala Thr Gln Met Arg Lys
    130                 135                 140
Leu Thr Ser Asn Leu Arg Ile Gly Phe Gly Ala Phe Val Asp Lys Pro
145                 150                 155                 160
Val Ser Pro Tyr Met Tyr Ile Ser Pro Pro Glu Ala Leu Glu Asn Pro
                165                 170                 175
```

RAW SEQUENCE LISTING DATE: 01/16/2002
PATENT APPLICATION: US/09/673,302 TIME: 18:30:22

Input Set : A:\CO5043US.txt
Output Set: N:\CRF3\01162002\I673302.raw

```
80 Cys Tyr Asp Met Lys Thr Thr Cys Leu Pro Met Phe Gly Tyr Lys His
81             180                 185                 190
84 Val Leu Thr Leu Thr Asp Gln Val Thr Arg Phe Asn Glu Glu Val Lys
85         195                 200                 205
88 Lys Gln Ser Val Ser Arg Asn Arg Asp Ala Pro Glu Gly Gly Phe Asp
89     210                 215                 220
92 Ala Ile Met Gln Ala Thr Val Cys Asp Glu Lys Ile Gly Trp Arg Asn
93 225                 230                 235                 240
96 Asp Ala Ser His Leu Leu Val Phe Thr Thr Asp Ala Lys Thr His Ile
97                 245                 250                 255
100 Ala Leu Asp Gly Arg Leu Ala Gly Ile Val Gln Pro Asn Asp Gly Gln
101             260                 265                 270
104 Cys His Val Gly Ser Asp Asn His Tyr Ser Ala Ser Thr Thr Met Asp
105         275                 280                 285
108 Tyr Pro Ser Leu Gly Leu Met Thr Glu Lys Leu Ser Gln Lys Asn Ile
109     290                 295                 300
112 Asn Leu Ile Phe Ala Val Thr Glu Asn Val Val Asn Leu Tyr Gln Asn
113 305                 310                 315                 320
116 Tyr Ser Glu Leu Ile Pro Gly Thr Thr Val Gly Val Leu Ser Met Asp
117                 325                 330                 335
120 Ser Ser Asn Val Leu Gln Leu Ile Val Asp Ala Tyr Gly Lys Ile Arg
121             340                 345                 350
124 Ser Lys Val Glu Leu Glu Val Arg Asp Leu Pro Glu Glu Leu Ser Leu
125         355                 360                 365
128 Ser Phe Asn Ala Thr Cys Leu Asn Asn Glu Val Ile Pro Gly Leu Lys
129     370                 375                 380
132 Ser Cys Met Gly Leu Lys Ile Gly Asp Thr Val Ser Phe Ser Ile Glu
133 385                 390                 395                 400
136 Ala Lys Val Arg Gly Cys Pro Gln Glu Lys Glu Lys Ser Phe Thr Ile
137                 405                 410                 415
140 Lys Pro Val Gly Phe Lys Asp Ser Leu Ile Val Gln Val Thr Phe Asp
141             420                 425                 430
144 Cys Asp Cys Ala Cys Gln Ala Gln Ala Glu Pro Asn Ser His Arg Cys
145         435                 440                 445
148 Asn Asn Gly Asn Gly Thr Phe Glu Cys Gly Val Cys Arg Cys Gly Pro
149     450                 455                 460
152 Gly Trp Leu Gly Ser Gln Cys Glu Cys Ser Glu Glu Asp Tyr Arg Pro
153 465                 470                 475                 480
156 Ser Gln Gln Asp Glu Cys Ser Pro Arg Glu Gly Gln Pro Val Cys Ser
157                 485                 490                 495
160 Gln Arg Gly Glu Cys Leu Cys Gly Gln Cys Val Cys His Ser Ser Asp
161             500                 505                 510
164 Phe Gly Lys Ile Thr Gly Lys Tyr Cys Glu Cys Asp Asp Phe Ser Cys
165         515                 520                 525
168 Val Arg Tyr Lys Gly Glu Met Cys Ser Gly His Gly Gln Cys Ser Cys
169     530                 535                 540
172 Gly Asp Cys Leu Cys Asp Ser Asp Trp Thr Gly Tyr Tyr Cys Asn Cys
173 545                 550                 555                 560
176 Thr Thr Arg Thr Asp Thr Cys Met Ser Ser Asn Gly Leu Leu Cys Ser
```

RAW SEQUENCE LISTING DATE: 01/16/2002
PATENT APPLICATION: US/09/673,302 TIME: 18:30:22

Input Set : A:\CO5043US.txt
Output Set: N:\CRF3\01162002\I673302.raw

```
177                 565                 570                 575
180 Gly Arg Gly Lys Cys Glu Cys Gly Ser Cys Val Cys Ile Gln Pro Gly
181             580                 585                 590
184 Ser Tyr Gly Asp Thr Cys Glu Lys Cys Pro Thr Cys Pro Asp Ala Cys
185         595                 600                 605
188 Thr Phe Lys Lys Glu Cys Val Glu Cys Lys Lys Phe Asp Arg Gly Ala
189     610                 615                 620
192 Leu His Asp Glu Asn Thr Cys Asn Arg Tyr Cys Arg Asp Glu Ile Glu
193 625                 630                 635                 640
196 Ser Val Lys Glu Leu Lys Asp Thr Gly Lys Asp Ala Val Asn Cys Thr
197                 645                 650                 655
200 Tyr Lys Asn Glu Asp Asp Cys Val Val Arg Phe Gln Tyr Tyr Glu Asp
201             660                 665                 670
204 Ser Ser Gly Lys Ser Ile Leu Tyr Val Val Glu Glu Pro Glu Cys Pro
205         675                 680                 685
208 Lys Gly Pro Asp Ile Leu Val Val Leu Leu Ser Val Met Gly Ala Ile
209     690                 695                 700
212 Leu Leu Ile Gly Leu Ala Ala Leu Leu Ile Trp Lys Leu Leu Ile Thr
213 705                 710                 715                 720
216 Ile His Asp Arg Lys Glu Phe Ala Lys Phe Glu Glu Glu Arg Ala Arg
217                 725                 730                 735
220 Ala Lys Trp Asp Thr Ala Asn Asn Pro Leu Tyr Lys Glu Ala Thr Ser
221             740                 745                 750
224 Thr Phe Thr Asn Ile Thr Tyr Arg Gly Thr
225         755                 760
228 <210> SEQ ID NO: 2
229 <211> LENGTH: 66
230 <212> TYPE: PRT
231 <213> ORGANISM: Mus musculus
233 <220> FEATURE:
234 <221> NAME/KEY: misc_feature
235 <223> OTHER INFORMATION: Segment of GPIIIa beta-3 subunit
238 <220> FEATURE:
239 <221> NAME/KEY: misc_feature
240 <222> LOCATION: (41)..(66)
241 <223> OTHER INFORMATION: Xaa may be present or missing and may be any variable
244 <400> SEQUENCE: 2
246 Lys Leu Leu Leu Thr Thr His Asp Arg Lys Glu Phe Ala Lys Phe Glu
247 1               5                  10                  15
250 Glu Glu Arg Ala Arg Ala Lys Trp Asp Thr Ala Asn Asn Pro Leu Tyr
251             20                  25                  30
W--> 254 Lys Glu Ala Thr Ser Thr Phe Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
255         35                  40                  45
W--> 258 Asn Ile Thr Tyr Arg Gly Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
259     50                  55                  60
W--> 262 Xaa Xaa
263 65
266 <210> SEQ ID NO: 3
267 <211> LENGTH: 66
```

see item 5 on Error Summary Sheet
amino acid
variable length is invalid.

RAW SEQUENCE LISTING DATE: 01/16/2002
PATENT APPLICATION: US/09/673,302 TIME: 18:30:22

Input Set : A:\CO5043US.txt
Output Set: N:\CRF3\01162002\I673302.raw

<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Segment of GPIIIa beta-6 subunit
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (41)..(48)
<223> OTHER INFORMATION: Xaa may be present or missing and may be any variable
<400> SEQUENCE: 3

```
Lys Leu Leu Val Ser Phe His Asp Arg Lys Glu Val Ala Lys Phe Glu
1               5                  10                  15
Ala Glu Arg Ser Lys Ala Lys Trp Gln Thr Gly Thr Asn Pro Leu Tyr
            20                  25                  30
W--> Arg Gly Ser Thr Ser Thr Phe Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
        35                  40                  45
Asn Val Thr Tyr Lys His Arg Glu Lys Gln Lys Val Asp Leu Ser Thr
    50                  55                  60
Asp Cys
65
```

<210> SEQ ID NO: 4
<211> LENGTH: 66
<212> TYPE: PRT
<213> ORGANISM: Mus musculus
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Segment of GPIIIa beta-1 subunit
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (41)..(66)
<223> OTHER INFORMATION: Xaa may be present of missing and may be any variable
<400> SEQUENCE: 4

```
Lys Leu Leu Met Leu Ile His Asp Arg Arg Glu Glu Ala Lys Glu Glu
1               5                  10                  15
Lys Glu Lys Met Asn Ala Lys Trp Asp Thr Gly Glu Asn Pro Ile Tyr
            20                  25                  30
W--> Lys Ser Ala Val Thr Thr Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
        35                  40                  45
W--> Asn Pro Lys Tyr Glu Gly Lys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
    50                  55                  60
W--> Xaa Xaa
65
```

<210> SEQ ID NO: 5
<211> LENGTH: 66
<212> TYPE: PRT
<213> ORGANISM: Mus musculus
<220> FEATURE:
<221> NAME/KEY: misc_feature
<223> OTHER INFORMATION: Segment of GPIIIa beta-5 subunit

RAW SEQUENCE LISTING DATE: 01/16/2002
PATENT APPLICATION: US/09/673,302 TIME: 18:30:22

Input Set : A:\CO5043US.txt
Output Set: N:\CRF3\01162002\I673302.raw

352 <220> FEATURE:
353 <221> NAME/KEY: misc_feature
354 <222> LOCATION: (58)..(66)
355 <223> OTHER INFORMATION: Xaa may be present or missing and may be any variable
358 <400> SEQUENCE: 5
360 Lys Leu Leu Val Thr Ile His Asp Arg Arg Glu Phe Ala Lys Phe Gln
361 1 5 10 15
364 Ser Glu Arg Ser Arg Ala Arg Tyr Glu Met Ala Ser Asn Pro Leu Tyr
365 20 25 30
368 Arg Lys Pro Ile Ser Thr His Thr Val Asp Phe Thr Phe Asn Lys Phe
369 35 40 45
W--> 372 Asn Lys Ser Tyr Asn Gly Thr Val Asp Xaa Xaa Xaa Xaa Xaa Xaa Xaa
373 50 55 60
W--> 376 Xaa Xaa
377 65
380 <210> SEQ ID NO: 6
381 <211> LENGTH: 66
382 <212> TYPE: PRT
383 <213> ORGANISM: Mus musculus
385 <220> FEATURE:
386 <221> NAME/KEY: misc_feature
387 <223> OTHER INFORMATION: Segment of GPIIIa beta-2 subunit
390 <220> FEATURE:
391 <221> NAME/KEY: misc_feature
392 <222> LOCATION: (28)..(66)
393 <223> OTHER INFORMATION: Xaa may be present or missing and may be any variable
396 <400> SEQUENCE: 6
398 Lys Ala Leu Thr His Leu Ser Asp Leu Arg Glu Tyr Arg Arg Phe Glu
399 1 5 10 15
W--> 402 Lys Glu Lys Leu Lys Ser Gln Trp Asn Asn Asp Xaa Asn Pro Leu Phe
403 20 25 30
W--> 406 Lys Ser Ala Thr Thr Thr Val Met Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
407 35 40 45
W--> 410 Asn Pro Lys Phe Ala Glu Ser Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
411 50 55 60
W--> 414 Xaa Xaa
415 65
418 <210> SEQ ID NO: 7
419 <211> LENGTH: 66
420 <212> TYPE: PRT
421 <213> ORGANISM: Mus musculus
423 <220> FEATURE:
424 <221> NAME/KEY: misc_feature
425 <223> OTHER INFORMATION: Segment of GPIIIa beta-7 subunit
428 <220> FEATURE:
429 <221> NAME/KEY: misc_feature
430 <222> LOCATION: (41)..(66)
431 <223> OTHER INFORMATION: Xaa may be present or missing and may be any variable
434 <400> SEQUENCE: 7

Use of n or Xaa has been detected in the Sequence Listing. In the Sequence Listing, please include a corresponding explanation as presented in the <220> to <223> fields of each sequence using n or Xaa.

FSI

Please correct this error in Seq. 8, if shown

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/673,302

DATE: 01/16/2002
TIME: 18:30:23

Input Set : A:\CO5043US.txt
Output Set: N:\CRF3\01162002\I673302.raw

L:254 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:258 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:262 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:292 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:330 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:334 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:338 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:372 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:376 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:402 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:406 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:410 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:414 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6
L:444 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:448 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:452 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7
L:472 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:476 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:480 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:484 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8
L:488 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8